Highlights

  • 4DMedical Limited (ASX:4DX) operates in software-based lung imaging and respiratory diagnostic technology.
  • For FY26, 4DMedical reported operating revenue of approximately A$7.1 million, up 21%, and adjusted net loss of approximately A$32.9 million.
  • The company said it delivered 344,075 scans during FY26, a 77% increase, including 105,970 scans in the fourth quarter.
  • The company provides ongoing updates about financial reporting, operational priorities and associated risks.

4DMedical Limited (ASX:4DX) is involved in software-based lung imaging and respiratory diagnostic technology. The company develops XV Technology and Imbio-related imaging capabilities, with products designed to support assessment of pulmonary function through clinical imaging workflows. It supplies software-based solutions to healthcare organisations. During trading on 20 October 2026, 4DMedical Limited (ASX:4DX) was quoted at AUD 3.765, down -2.71% for the session. The company’s recent disclosures place its operating position and capital requirements in the context of its 2026 reporting cycle.

Company Business

4DMedical Limited (ASX:4DX) conducts business through the activities described in its current corporate materials. The company develops XV Technology and Imbio-related imaging capabilities, with products designed to support assessment of pulmonary function through clinical imaging workflows. It supplies software-based solutions to healthcare organisations. Understanding this operational structure matters because revenue, costs and investment can originate in different activities, and not every activity contributes to earnings at the same stage of development. The company’s ability to fund its operations and meet regulatory or customer requirements remains relevant to its reporting.

Recent Development

The company said it delivered 344,075 scans during FY26, a 77% increase, including 105,970 scans in the fourth quarter. Its software products were being delivered at 540 sites globally at 30 June 2026, and the company reported A$278 million in cash at that date. The sequence of 2026 disclosures provides a basis for assessing what has been completed and what remains subject to further reporting. 4DMedical Limited (ASX:4DX) may publish further operational updates as its reporting timetable and business milestones progress.

Financial Performance and Sector Context

For FY26, 4DMedical reported operating revenue of approximately A$7.1 million, up 21%, and adjusted net loss of approximately A$32.9 million. The statutory result included a substantial non-cash remeasurement of a financial debt instrument, which differs from the company’s adjusted loss measure. Reported revenue, earnings, cash and operational statistics should be considered according to their stated accounting definitions and the period covered. For 4DMedical Limited (ASX:4DX), these distinctions are material because activity levels and accounting outcomes can differ. Industry conditions also shape the commercial environment: procurement, regulation, labour, capital availability or sector-specific demand may influence costs and operating decisions. Where company filings distinguish statutory and underlying measurements, the measures should not be treated as interchangeable.

Risks to Consider

Risks include hospital procurement cycles, medical regulation, validation requirements, commercial conversion, software deployment and the difference between accounting losses and underlying cash usage. 4DMedical Limited (ASX:4DX) also operates within a setting where changes to regulation, counterparties, operating costs or implementation schedules can affect reported results. The timing and extent of any impact cannot be established from a share quotation alone. Operational announcements should therefore be distinguished from financial recognition and completed outcomes.

What to Watch Next

Changes in scan volumes, paying customer locations, contract receipts and adoption of CT:VQ can help distinguish operational use from recognised financial revenue. Future announcements from 4DMedical Limited (ASX:4DX) can be assessed against the specific targets, reported periods and definitions used in the company’s official disclosures. Follow-up statements may provide further information about funding, delivery timetables, customer activity or financial trends. Those measures provide clearer evidence than attributing daily share-price fluctuations to older news.

Key Insights

4DMedical Limited (ASX:4DX) has reported 2026 activities that reflect its particular operating model and the economic or clinical requirements of its sector. The company said it delivered 344,075 scans during FY26, a 77% increase, including 105,970 scans in the fourth quarter. Changes in scan volumes, paying customer locations, contract receipts and adoption of CT:VQ can help distinguish operational use from recognised financial revenue. Its financial position and next operational milestones should be considered through subsequent official updates, without treating a single trading session as evidence of a change in the underlying business.